Neal G. Koller
President & Chief Executive Officer
President & Chief Executive Officer
- 3724a Thomas Point Road
Annapolis, Maryland 21403
USA
Tel: +1 443 994 0101
Fax: +1 410 990 9817
nkoller@plurogen.com
| PluroGen Therapeutics, Inc. 503 Broadleaf Way Charlottesville, Virginia 22911 USA Tel: +1 443 994 0101 Fax: +1 410 990 9817 www.plurogen.com |
October 5, 2007
RE: PluroGen Therapeutics Q3 2007 Investor Update
Dear Investor
PluroGen has had another terrific quarter, achieving a number of very important milestones in the 3rd quarter 2007.
This Quarterly Report focuses on these key milestones. We are pleased with our progress and are happy to answer any
of your questions. Thank you for your investment and support.
Q3 '07 Update – Important Achievements for PluroGen
Regulatory & Clinical
Product Development
Intellectual Property
Manufacturing
Funding
We would like to thank you for your interest and your investment in PluroGen. With your support, we have been able to
move this technology significantly forward and hope this update is informative. If you have any questions please do not
hesitate to contact us. We are happy to talk further and provide any answers.
Best regards,
Neal G. Koller
NGK/sa
RE: PluroGen Therapeutics Q3 2007 Investor Update
Dear Investor
PluroGen has had another terrific quarter, achieving a number of very important milestones in the 3rd quarter 2007.
This Quarterly Report focuses on these key milestones. We are pleased with our progress and are happy to answer any
of your questions. Thank you for your investment and support.
Q3 '07 Update – Important Achievements for PluroGen
Regulatory & Clinical
- Submitted our 1st US FDA Orphan Drug Application
- Completed 1st meetings with our #1 candidate for EU regulatory partner
Product Development
- Signed agreement with Derma Sciences, Inc. (NASDQ: DSCI) a well established wound care company to
prototype our next round of products
- These products are dressing products, that is biomaterials impregnated with our gel products to make
advanced bandages, for burns and wounds - Terms of the agreement include the partner company paying for all prototyping work and the partner
company exclusively licensing any new intellectual property to PluroGen
Intellectual Property
- Signed the renegotiated license agreement with UVA
- This new license provides for more favorable terms on our gel technology platform
- This new license includes the new provisional patent covering our gel technology filed in June
Manufacturing
- Final formulation selected for our 1st product
- built more than 140 formulation prototypes
- Initial response to our selected formulation was very positive from the prestigious Shriners Burn Hospital
in Cincinnati
Funding
- Raised to date USD 200,000 in the bridge round, bringing total raised to USD 1.8M
- Series A Offering
- Early meetings have been initiated with potential investors, including several VC firms. Discussions are
positive but no firm commitments.
We would like to thank you for your interest and your investment in PluroGen. With your support, we have been able to
move this technology significantly forward and hope this update is informative. If you have any questions please do not
hesitate to contact us. We are happy to talk further and provide any answers.
Best regards,
Neal G. Koller
NGK/sa